{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["104(9)"],"submitter":["Kucukyurt S"],"pubmed_abstract":["Primary mediastinal B-cell lymphoma (PMBCL) is a rare and distinct subtype of non-Hodgkin lymphoma. No consensus exists on optimal frontline treatment, and the use of R-CHOP ± radiotherapy (RT) and DA-EPOCH-R ± RT remains common, yet comparative real-world data are limited. In our multicenter retrospective study, we analyzed PMBCL patients, stratified by the first-line therapy (R-CHOP-21 ± RT or DA-EPOCH-R ± RT). Primary outcomes were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS), alongside assessment of treatment-related toxicities and prognostic factors for PFS and OS. We included 157 patients [R-CHOP ± RT group (n = 80) and DA-EPOCH-R ± RT group (n = 77)] with a median age of 31 years, of whom 68.2% were female. CR rates were similar for R-CHOP "],"journal":["Annals of hematology"],"pagination":["4679-4690"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12552371"],"repository":["biostudies-literature"],"pubmed_title":["Real-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients."],"pmcid":["PMC12552371"],"pubmed_authors":["Dogan A","Dilek I","Akın S","Unal A","Yigitbası A","Yeral M","Terzi Demirsoy E","Keklik Karadag F","Kucukyurt S","Goren D","Ipek Y","Kaygusuz Atagunduz I","Ciftciler R","Ozgur Y","Kurt Yuksel M","Erdogan Ozunal I","Sahin F","Yıldız A","Uysal A","Barısta I","Koca O","Baysal M","Sahin O","Gunes AK","Ugur MC","Salim O","Selim C","Yuksel M","Afacan Ozturk HB","Tıglıoglu P","Guven S","Saydam G","Ayer M","Taser Kanat N","Pınar IE","Iltar U","Demir AM","Atalay F","Soyer Kosemehmetoglu O","Mehtap O","Birtas Atesoglu E","Eskazan AE","Ulukoylu Menguc M","Soyer N"],"additional_accession":[]},"is_claimable":false,"name":"Real-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients.","description":"Primary mediastinal B-cell lymphoma (PMBCL) is a rare and distinct subtype of non-Hodgkin lymphoma. No consensus exists on optimal frontline treatment, and the use of R-CHOP ± radiotherapy (RT) and DA-EPOCH-R ± RT remains common, yet comparative real-world data are limited. In our multicenter retrospective study, we analyzed PMBCL patients, stratified by the first-line therapy (R-CHOP-21 ± RT or DA-EPOCH-R ± RT). Primary outcomes were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS), alongside assessment of treatment-related toxicities and prognostic factors for PFS and OS. We included 157 patients [R-CHOP ± RT group (n = 80) and DA-EPOCH-R ± RT group (n = 77)] with a median age of 31 years, of whom 68.2% were female. CR rates were similar for R-CHOP ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-05T04:50:25.756Z","creation":"2026-05-13T14:29:17.987Z"},"accession":"S-EPMC12552371","cross_references":{"pubmed":["41074982"],"doi":["10.1007/s00277-025-06644-z"]}}